Effect of calaglitzin combined with Degu insulin liraglutide and pioglitazone metformin in the treatment of obese type 2 diabetes mellitus and its effect on insulin sensitivity
10.3760/cma.j.cn115807-20240508-00155
- VernacularTitle:卡格列净联合德谷胰岛素利拉鲁肽、吡格列酮二甲双胍治疗肥胖T2DM效果及对胰岛素敏感性影响
- Author:
Xiaoyi WANG
1
;
Zhen ZHANG
;
Jie HAN
;
Hui LIU
;
Chengcheng YANG
;
Huihui CHEN
Author Information
1. 商丘市第一人民医院药学部，商丘 476100
- Keywords:
Calaglizin;
Tegu insulin liraglutide;
Pioglitazone metformin;
Obesity;
Type 2 diabetes;
Insulin resitance
- From:
Chinese Journal of Endocrine Surgery
2024;18(5):728-732
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of calaglitzin combined with Degu insulin Liraglutide and pioglitazone metformin in the treatment of obese type 2 diabetes mellitus (T2DM) .Methods:Ninety-nine obese T2DM patients admitted to our hospital from Apr. 2021 to Jun. 2023 were divided into 2 groups according to different treatment methods. The control group ( n=52) were treated with Delgu insulin liraglutide and pioglitazone metformin; the observation group ( n=47) were treated with cagaglizin on the basis of the control group, and both groups were treated for 8 weeks. The therapeutic effect of the two groups was compared. Results:The effective rate of observation group was 95.74% (45/47), higher than that of control group 82.69% (43/52) ( P<0.05). After eight weeks of treatment, the levels of FPG (7.96±0.74) mmol/L, 2hPBG (8.36±1.02) mmol/L and BMI (24.63±1.51) kg/m 2 in the observation group were higher than those in the control group ( P<0.05). After 8 weeks of treatment, HOMA-IR (2.41±0.56) of observation group was lower than that of control group (2.84±0.61), GIR (5.63±0.97) mg·kg -1·min -1 was higher than that of the control group (5.17±0.95) mg·kg -1·min -1 ( P<0.05). After eight weeks of treatment, the levels of TG (4.22±0.43) mmol/L, TC (2.15±0.21) mmol/L and ApoB (1.18±0.14) mmol/L in the observation group were higher than those in the control group (2.49±0.26) mmol/L, (4.69±0.47) mmol/L and (1.45±0.19) mmo l/L ( P<0.05). The incidence of adverse reactions in the observation group was 8.51% (4/47), lower than that in the control group (5.77% (3/52) ( P>0.05) . Conclusion:Taking calaglitzin in combination with Delgu insulin liraglutide and pioglitazone metformin can significantly reduce insulin resistance, increase the sensitivity of peripheral tissues to insulin, reduce blood glucose level and BMI level, and the drug safety is reasonable.
